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Radiotherapy plays a key role in the treatment of cancer with over
50% of individuals now receiving radiation at some time during
the course of their disease. The increasing number of men
requiring radiotherapy impacts on supportive services such as
follow-up care. Current management of radiotherapy is focused on
treatment provided on an outpatient basis. Monitoring for side
effects is at regular clinic visits, when there may be little opportu-
nity for discussion of the impact of treatment (Rotman et al, 1977;
Strohl, 1988). Traditional approaches to the monitoring of radio-
therapy treatment focus primarily on physical symptoms and
response to treatment (Steinberg and Rose, 1996). Questions are
now arising as to the effectiveness of these services, especially
when economic restraints and growing patient numbers put
traditional patterns of care under pressure. 
It has been suggested that specialist nurses have the potential to
play a central role in identifying symptoms of disease, adverse
effects of radiotherapy, clinical management and in promoting
health. Brown and Grimes’ (1993) meta analysis of nurse practi-
tioner care, found that specialist nursing was more focused on
promoting health than standard medical care which resulted in
increased satisfaction with care and was cost effective. Richardson
and Maynard (1995) in an economic review of the possibility of
exchanging medical and nursing roles, contested these findings
and were less certain that these nurse practitioner roles could be
implemented in the United Kingdom. They cite the increased
education level of nurses in the USA and argue that these roles
would be difficult to apply in the National Health Service.
However, a growing number of studies in the UK are demon-
strating the value that such specialist nursing can provide
(Ridsdale et al, 1997). 
In radiotherapy, attempts have been made to study how specialist
nursing can be implemented. Norcross Weintraub (1990) per-
formed a randomised trial in the USA comparing health education
or the provision of specialist nursing against conventional care.
They suggested advantages for the role of the radiotherapy nurse,
but this study was under-powered and unable to provide statistical
evidence of these benefits. A descriptive study in the UK of the
provision of a specialist nurse for those undergoing cranial irradia-
tion found a subsequent 30% reduction in medical workload (James
et al, 1994). A more recent observational study found that specialist
nurses within a radiotherapy setting provided greater interaction
and initiated more supportive care than there medical colleagues.
The authors suggest that this model of care may provide more
effective support for patients undergoing radiotherapy (Campbell et
al, 2000). However, few of these studies have observed patient
outcomes or explored the economic implications of such a nurse-
led service. 
The issue of utilising specialist nurses, as a substitute for
medical care, is topical but rarely evaluated. Evaluation of a
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patients. We evaluated the effectiveness of nurse-led follow up vs.
conventional medical care and investigated how these services
managed symptoms and patients’ quality of life. Overall evalua-
tion of the service included satisfaction with health care and
economic costs. The hypothesis was that the provision of nurse-led
care would reduce side effects of therapy and improve quality of
life for men undergoing pelvic radiotherapy. A secondary hypoth-
esis was that nurse-led care would increase patients’ satisfaction
and reduce costs. 
METHODS 
Men included in the study were those undergoing radical (greater
than 60 Gy) radiotherapy for prostate or bladder cancer. They
were randomised either to a group receiving conventional care
(control), or to a group receiving instead care from a clinical
nurse specialist (intervention). Both groups had toxicitys from
treatment monitored and their quality of life and perception of
symptom severity assessed. Randomisation was carried out by
the Clinical Trials Unit, Institute of Cancer Research, Sutton, and
was stratified to provide a balanced representation of men with
prostate and bladder cancer in the 2 randomised groups. Men were
approached for consent in the planning stages of radiotherapy and
asked to participate in the trial at start of radiotherapy. Out of
the 131 of those eligible, 6 men refused, not wishing to have
nurse-led care and 11 were missed due to starting radiotherapy
prior to the researcher being able to access them. In total 115
(85%) of those undergoing radical treatment were involved in
the study. 
Radiotherapy was CT (computerised tomography) planned and
delivered using 5–10 MeV linear accelerators, generally using 3
field techniques with anterior and lateral or posterior oblique
fields. For men with prostate cancer the target volume was the
prostate (± seminal vesicles) treated with a 1.0–1.5 cm margin.
Conformal radiotherapy methods and treatment delivery using a
multileaf collimator was used for 25 men treated in a dose-escalation
study. The remaining patients were treated with conventionally
collimated fields. All radiotherapy fields were treated daily using
conventional 2 Gy fractions to give a total dose of 64–74 Gy
prescribed to the isocentre. For patients with bladder cancer, the
whole bladder or tumour was treated with a 1.5–2 cm margin using
conventional radiotherapy methods and 2 Gy daily fractions to a
total dose of 60–64 Gy. Both the control and intervention groups
were assessed within the first week of starting radiotherapy, week
3, 6 and at 12 weeks following start of radiotherapy (Figure 1). It
was estimated that 164 patients would be required to detect an
absolute difference of 20% in morbidity between the 2 groups of
the study (α = 0.05, power 80%). Morbidity was defined as a
difference of 20% in severity of urinary symptoms and decreased
global quality of life at 6 weeks, when acute radiotherapy side
effects would be expected to be most pronounced. 
Accrual to the study was lower than anticipated for 2 reasons.
Firstly, fewer men than expected were receiving radical radio-
therapy for bladder cancer. Secondly, although a second centre
was expected to participate it did not in the end enter patients. In
consequence the data were reviewed after one year by an indepen-
dent data monitoring committee (DMC). The reduced accrual
resulted in a predicted shortfall of 40 patients. On the advice of the
DMC, the study was closed to recruitment and follow up of
existing subjects continued. 
Assessment of symptoms and quality of life 
Data were collected longitudinally with observer-rated toxicity
scores and self-assessment of symptoms, quality of life, experi-
ence and satisfaction with care measures. The RTOG/EORTC
(Cox et al, 1995) observer-rated toxicity scale provided a conven-
tional measure with which to compare the acute toxicity of symp-
toms between the 2 groups and was completed pre-treatment and
at 1, 3, 6 and 12 weeks from start of radiotherapy. Both the
specialist nurse and physicians undertaking clinics collected data.
In order to define inter-observer variation a subgroup of patients 
(n = 49) was assessed independently from the 2 clinics by another
clinician and, out of 490 total observations, there was a 96%
agreement in scores. Self-assessment of symptoms was by using a
13-item questionnaire with 100 mm visual analogue scales, which
monitored not only the occurrence and severity, but also the
distress, and more global impact that these symptoms had on daily
activities. This self-assessment questionnaire was developed from
semi-structured interviews in a similar patient group (Faithfull,
1995). Participants completed this assessment during their first
week of radiotherapy and after 3, 6 and 12 weeks. The EORTC
QLQ-C30 (Aaronson et al, 1993) was used to explore the indivi-
duals’ psychosocial adjustment to their illness and perceived
severity of physical symptoms. The questionnaire covered several
areas of quality of life, the physical, emotional, cognitive, social
and role functioning effects as well as global quality of life. This
was completed within the first week of starting radiotherapy, week
6 and 12. 
Assessment of satisfaction and economic costs 
Overall satisfaction with the clinical care was evaluated using a
self-assessment questionnaire. This was given to participants 12
weeks from start of radiotherapy (n = 115) and requested to be
returned anonymously by post (n = 108). This tool was based on
the Newcastle satisfaction with nursing scale (Thomas and
MacMillan, 1995) which was developed by eliciting patients’
concepts of good and unsatisfactory care. The questionnaire was
designed to identify and discriminate between different types of
ward organisation and it has been shown to be valid and reliable in
this context. The questionnaire explored domains such as informa-
tion provision, interpersonal skills and communication, continuity
of care, symptom management and awareness of patient needs.
For this study it was adapted to reflect a more general interpreta-
tion of health care organisation from an outpatient basis and there-
fore results should be interpreted in this context. Changes to the
questionnaire were to replace nurse with doctor/nurse in all ques-
tions and remove 14 specific inpatient enquiries such as night care
experience. A further 9 questions were removed in seeking
patients opinions of health care as they focused on ward-based
health-care activity. Costs were based on the hospital accounting
system and prescription records, drug costs were standardised
from the date of analysis so that comparisons could be made longi-
tudinally (Yates, 1998). Health-care costs were analysed in units.
Separate unit costs were calculated for medications, microbiology
investigations and services utilised during the 3 months a partici-
pant was part of the study. Service utilisation included relevant
salaries, including nursing and medical salaries, equipment costs
and rental of accommodation. Patient costs such as time off work
or travel to the hospital, were not included. The costs of radio-
therapy treatment were also not included as these were relatively
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hospital, either as a day case or for overnight stay, outpatient
appointments and any additional services such as visits to the
radiotherapy nurse. The economic costs should be reviewed as a
unit of comparison rather than the ‘real’ costs of follow-up care
from radiotherapy. 
Intervention and control approach 
The nurse-led care (intervention) provided a separate service
specifically for patients within the study. Contact was established
at start of therapy and was continued throughout treatment until 12
weeks from start of radiotherapy, when patients returned to
medical care. The specialist nurse at initial contact provided infor-
mation and answered patient questions. The nurse also provided
men and their families with leaflets on healthy eating, radiotherapy
and how to manage urinary symptoms during radiotherapy.
Attendance at the nurse-led clinic was organised for within the
first week and last week of radiotherapy. Further appointments
could be negotiated as required. Telephone contact was maintained
between clinic appointments to assess health status. Nurse-led
outpatients appointments were for 20 minutes. The intervention
approach was based on exploring the individual’s understanding of
their cancer diagnosis, symptoms and the meaning of the illness.
The provision of information and practical advice on how to
recognise early symptoms, what to expect from treatment and how
to manage existing problems were considered. A protocol of
medication and management for symptoms was agreed with the
responsible consultants (Figure 2). 
Conventional care (control) consisted of routine medical
appointments lasting 10 minutes within the urology outpatient
setting. These were arranged routinely at start of radiotherapy
treatment at either weekly (for men with bladder cancer) or 
2-weekly (for those with prostate cancer) intervals. These appoint-
ments continued throughout the duration of therapy. This was a
consultant-led clinic with a group of 6 physicians, 2 of whom were 
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Patients randomised between September 1995–January 1997
(n = 115)
Total population undergoing radical radiotherapy within this time
period (n =136)
Patients who refused entry to study (n = 6)
Missed (n = 11)
Patients not eligible (n = 4)
INTERVENTION
NURSE LED CARE
Initial assessments at first clinical
appointment then open access
clinics until completion of
radiotherapy. Telephone contact
and then return to medical care 12
weeks following treatment.
(n = 58)
CONTROL
CONVENTIONAL MEDICAL
FOLLOW-UP
Routine outpatient clinics two
weekly until completion of
treatment then 12 weeks follow-up
appointments.
(n = 57)
RTOG/EORTC Toxicity scores
Completed pre-treatment at weeks 1, 3, 6 & 12
by physician or nurse
EORTC QLQ C30
Completed by patient in weeks 1, 6 & 12
SELF-ASSESSMENT QUESTIONNAIRE OF
SYMPTOMS completed by patient in weeks
1, 3, 6 &12
SATISFACTION QUESTIONNAIRE
completed at week 12 following radiotherapy
anonymously by patients at home
ECONOMIC APPRAISAL information
collected on unit costs over 3 months from time
of entering study:
ASSESSMENTS
during and after
radiotherapy
Figure 1 Design of randomised controlled trial of nurse-led care v standard medical care in patients with prostate and bladder cancer undergoing pelvic
radiotherapy pre-fellowship registrars, 2 post-fellowship registrars and 2 medi-
cal research fellows. Medical care consisted of assessment of
toxicity, symptom management and monitoring of progress
through treatment. Following treatment patients returned to clinic
12 weeks from start of radiotherapy. 
Both intervention and control group had access to outpatient
nurses and a radiotherapy nurse based within the treatment suite.
Auditing of radiotherapy treatment planning and delivery was
assessed weekly within a multi-disciplinary team for all patients in
the trial. 
Statistical methods 
Data were analysed in 3 ways firstly by comparing data at cross-
sectional time points at week 1, 3, 6 and 12 from start of radio-
therapy, secondly using self-assessed symptoms as a general linear
model over the time of radiotherapy and thirdly evaluating the
health-care costs and satisfaction with care. This provided data that
compared data at key time points as well as across the treatment
trajectory. For self assessment of symptoms an algorithm was used
that transformed scores for the individual items that made up each
symptom which determined the total symptom scores (Mathews
et al, 1990). This gave a composite score potentially ranging from
0–100 that included the severity, occurrence and distress of that
symptom. As can be expected with quality of life scores, data were
not normally distributed and non-parametric significance tests
were carried out, generally based on the Mann–Whitney U test.
RTOG scores were assessed for association between randomised
groups using χ 2 tests. Toxicity scores were dichotomised into low-
toxicity RTOG 1 and 2 scores or severe toxicity which included
RTOG scores greater than 2. These scores reflected maximum
change in toxicity from pre-radiotherapy scores. 
Secondly multivariate analysis was conducted to explore how
randomisation, demographic and treatment factors influenced
symptom severity. Men were coded as having high or low
symptom scores at 6 weeks according to whether they fell above
or below the median score. These codes formed the basis of the
multiple regression analysis. Thirdly satisfaction scores collected
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Symptoms.
Review two
week  ly
Assess symptoms
Is it due to infection?
Physical examination to exclude
overflow or obstruction
Check for constipation and treat
SCORE
1.Dribbling of urine post micturition
2. Passing small volume of urine when
 coughing, laughing etc. (stress incontinence)
3.Leaking small volume before being able to
get to the toilet
4. Nocturnal enuresis
5. No control over passing urine
TREATMENT
If score = 1 advise patient to wait a few seconds after passing urine
to allow bladder to empty.
Give male patients a copy of leaflet ’for men a common problem’
If score =                 2 Advise on pelvic floor exercises and prescribe oxybutin
or amitriptyline if no other cause found.
If score > 2 refer to community continence adviser and establish
causation.
Symptoms of
involuntary passing
urine. Described as
leak age
No
Yes
Is this a new
symptom since starting
radiotherapy?
Yes
No
At risk of urinary leak  age.
Previous surgery to the bladder
such as TURP or cystoscopy
Assess frequency/volume advise to
complete a self assessment chart.
if necessary give supply of drip collectors
/pads
If fluid intak  e  >  2L/24  hrs,
advise:
to reduce fluid intak  e.
avoid alcohol & drink  s
containing caffeine.
Establish level of distress.
Check supplies of pads.
Refer to community
services if necessary
Check urine for presence of
leuk  ocytes & nitrites. If present
send an MSU and treat any
infection
Figure 2 Example of algorithm of protocol for the management of urinary incontinence at 12 weeks were based on an algorithm score comparing the
experience and satisfaction with care (Thomas and MacMillan,
1995). Questions were first re-coded to reflect scores from 0–6, the
questions were then summed and divided by the number of validly
answered scores within that question. This was then divided by 6
(number of codes) and multiplied by 100 to give a global score
where 100 represented the best possible experience. Economic
costs were gathered through patient records and hospital data base,
these were summed and analysed based on the Mann–Whitney U
test. 
The compliance rate for completion of questionnaires was vari-
able across the time points with fewer assessments being com-
pleted later on during follow-up, this resulted in missing data. This
non-response was partly as a result of a reliance on questionnaires
being distributed during outpatient clinics, so patients may not
have received assessments and possibly assessment fatigue. Self-
assessed symptom data that was completed was included in the
analysis despite missing data at some time points. Data were analys-
ed on a symptom-by-symptom analysis and if data were missing
from an element of that visual analogue scale this question was
excluded from the patient’s analysis. Quality of life data also
diminished over time partly for the same reason and partially
completed questionnaires were not considered in the analysis.
RTOG data were less of a problem as these were objective data
scored at the time of patient visits, there were therefore no missing
data in this data set. Partially completed satisfaction data were
addressed by adjustment of the algorithm to exclude the missing
data scores. 
RESULTS 
Patient characteristics 
Demographic data for all randomised patients are shown in Table 1.
There were no statistically significant differences in treatment,
stage of disease or patient characteristics between control and
intervention groups. Most of the men were elderly with a median
age of 70 and an age range from 40–83. This age was reflected in
employment history with over half of the population being retired.
The sample consisted mainly of men undergoing prostate cancer
treatment (83%) and a smaller proportion of men (17%) under-
going pelvic radiotherapy for bladder cancer. 
Questionnaire compliance was high initially (96%) but there
was a decrease in completion of questionnaires over time (88% at
week 6). There were also differences in rates of completion for
different questionnaires, for example at the 12-week time point
94% of satisfaction questionnaires and 81% of the EORTC
quality-of-life questionnaires were returned. 
Process of the clinics 
In the intervention group it was planned that patients returned to
medical care at 12 weeks. This joint medical and nursing appoint-
ment was counted as part of the intervention within the nursing
costs. However, 37 of the intervention patients had more than the
one planned medical appointment. 15 men had 2 medical appoint-
ments and 2 patients were seen on multiple occasions (7 clinic
appointments). The reasons for these extra medical appointments
were that these men had a medical problem needing prescriptions
not included in the protocol (Figure 2). Those men requiring
multiple appointments had co-morbid disease that required moni-
toring and prescriptions (diabetes and heart disease) and were
therefore seen by the nurse within the medical clinic. The mean
number of clinic appointments for the intervention group was 3.1
(range 1–8) compared to 5.8 (range 3–11) for the control group. In
the intervention group men received a total of 73.3 hours of
consultation time (a mean of 1.2 hours per patient) where as in the
control group men received 58.3 hours in total (a mean of 1.0
hours per patient). If the additional appointments with the radio-
therapy nurse are included this brings the total consulation time
with health carers to 96.3 hours for men in the intervention group
and 93.9 hours in the control group (mean 1.6 consultation hours
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Table 1 Demographic characteristics of patients taking part in the study 
Control Intervention Total 
(n = 57) (n = 58) (n = 115)
Age median (range) 70 (49–83) 70 (51–80) 70 (49–83) 
Diagnosis and stage 
Adenocarcinoma of prostate 47 (82%) 48 (83%) 95 (83%) 
T1 5 (11%) 4 (8%) 9 (9%) 
T2 16 (34%) 17 (38%) 33 (35%) 
T3 23 (49%) 27 (56%) 40 (53%) 
T4 3 (6%) 0 (0%) 3 (3%) 
Transitional cell cancer of the bladder 10 (18%) 10 (17%) 20 (17%) 
T1 0 (0%) 0 (0%) 0 (0%) 
T2 3 (30%) 2 (20%) 5 (25%) 
T3 5 (50%) 6 (60%) 11 (55%) 
T4 2 (20%) 2 (20%) 4 (20%) 
Radiation treatment dose 
60–64 Gy 48 (84%) 42 (72%) 90 (78%) 
74 Gya 9 (16%) 16 (28%) 25 (22%) 
Anterior field area (side of equivalent sq.) 
< 7.9 cm 5 (9%) 4 (7%) 9 (8%) 
8–10.9 cm 41 (72%) 44 (76%) 85 (74%) 
11 ≥ cm 11 (19%) 10 (17%) 21 (18%) 
aThe intervention group had a higher proportion of patients receiving 74 Gy treatment dosage, this was not statistically significant χ 2
P = 0.12. per patient over the course of the 12 weeks of the study for both
groups). 
Contact through bleep calls to the nurse specialist was docu-
mented, using a proforma for recording information, this was
collected over a period of 6 months. There were 24 uninitiated
calls for a range of reasons. Advice that was requested was on a
variety of concerns; 11 were primarily about managing cancer
symptoms and 1 enquiry about blood tests. A further 12 calls were
in relation to social difficulties, advice on other diseases and prac-
tical health care issues. Contact calls were not monitored for the
control group. 
Comparison between intervention and control groups
of symptoms and quality-of-life assessment at week 1 
Patients completed the symptom assessments on the first clinic
visit after beginning treatment, for 68% this was within the first
week and for 91% this was within 13 days of starting radiotherapy.
There were statistically significant differences in 7 of the symptom
scores at week 1 between intervention and control groups, which
we had not expected as the prediction would be that any benefits of
intervention would be at their greatest when side effects from
radiotherapy were at their maximum 6 weeks (Table 2). These
differences were found in symptoms most commonly seen with
prostate and bladder disease for example nocturia (P < 0.006),
fatigue (P < 0.04) and impact on activity from bladder symptoms
(P < 0.01). Men in the control group also had significantly more
constipation (P < 0.001). The nurse specialist saw the men at start
of therapy and the intervention focused on coping with urinary
symptoms, provided practical advice and explored current concerns
for those men commencing radiotherapy and this brief initial inter-
vention is a possible explanation for the differences observed.
Overall 52% (62% control group, 42% intervention group) of the
men on self assessment of symptoms considered they had urinary
symptoms that impacted on their daily activities to some degree.
Data from the observer-rated RTOG scale indicated that only 28%
of men had defined toxicity within the first week of treatment. Pre-
treatment the RTOG scores showed no differences between inter-
vention and control group. The RTOG assessment clearly focuses
on selected aspects of toxicity, whilst the self-assessment question-
naire reflects patients’ experience of symptoms, including whether
symptoms pre-date, or are a consequence of, radiotherapy. There
was no evidence of statistically significant differences in the
EORTC QLQ30 at week 1 and both groups had high quality-of-
life scores (Table 3). 
Comparison of symptoms and quality-of-life scores at
weeks 3, 6 and 12 
There were no significant differences in self-assessment scores at
week 3, 6 and 12. The differences observed at week 1 had disap-
peared. The median score for urinary frequency in the intervention
group (12) was higher at week 6 than in the control group (7), but
not significantly so. A large amount of missing data at this time
point prevented any conclusion being drawn about the longer-term
benefits of nurse-led care (Table 4). 
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Table 2 Assessment at week 1 for intervention and control groups for symptom self-assessment scale 
Measurements Randomisation Patient numbers Median *IQR 25/75 **P
Symptoms self assessment 
visual analogue scale 
(Higher scores represent more severe symptoms) 
Urinary frequency Intervention 55 7 0/17 0.35 
Control 54 8 0/27 
Urinary leakage Intervention 54 0 0/5 0.69 
Control 54 0 0/5 
Nocturia Intervention 52 11 7/24 0.006 
Control 53 22 11/42 
Pain with passing urine Intervention 56 0 0/3 0.07 
Control 54 0 0/13 
Activity and bladder symptoms Intervention 57 0 0/3 0.01 
Control 56 5 0/20 
Diarrhoea Intervention 56 0 0/5 0.43 
Control 53 0 0/7 
Constipation Intervention 56 0 0/0 0.001 
Control 54 2 0/10 
Cramp or abdominal pain Intervention 57 0 0/1 0.04 
Control 56 0 0/6 
Sore anus Intervention 57 0 0/3 0.44 
Control 53 0 0/6 
Activity and bowel symptoms Intervention 57 0 0/1 0.48 
Control 56 0 0/6 
Fatigue Intervention 56 2 0/10 0.04 
Control 55 9 0/24 
Sickness Intervention 57 0 0/0 0.01 
Control 55 0 0/2 
Feeling unwell Intervention 57 0 0/3 0.01 
Control 56 3 0/14 
*IQR = interquartile range.**Mann–Whitney U tests.There were also no significant differences in RTOG scores
between the intervention and control groups in terms of incidence
of side-effects. Bowel symptoms rated grade 1 were experienced
by 67% of the control group and 57% of the intervention group at
6 weeks. Only one man in the intervention group had toxicity of
grade 2 or greater. Men in the control group experienced more
severe bowel toxicity at 6 weeks, as defined by RTOG compared
with those in the intervention group. No significant difference
between groups was seen in maximum change in score from 
pre-radiotherapy (χ 2 trend, P = 0.4) for both bowel (Figure 3) and
bladder toxicitys (Figure 4). 
Quality-of-life assessments at weeks 6 and 12 (Table 5) showed
few differences between intervention and control groups. Functional
scores were again high overall, with some evidence of significant
difference between intervention and control groups in physical func-
tioning at 12 weeks (P = 0.05), suggesting that those in the interven-
tion arm were less physically impaired. Significantly higher levels
of constipation were seen at this time point in the control group,
compared with the intervention group (P = 0.01). 
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Table 3 Data at week 1 for intervention and control groups for EORTC QLQ-C30 variables 
Measurements Randomisation Patient numbers Median *IQR 25/75 **P
Functional scales (higher scores represent better functioning) 
Physical functioning Intervention 56 100 85/100 0.84 
Control 52 100 80/100 
Role functioning Intervention 57 100 100/100 0.26 
Control 53 100 100/100 
Emotional functioning Intervention 52 92 83/100 0.69 
Control 49 92 75/100 
Cognitive functioning Intervention 54 100 83/100 0.96 
Control 52 100 71/100 
Social functioning Intervention 56 100 83/100 0.67 
Control 53 100 83/100 
Global health status/QoL
Global quality of life Intervention 55 75 67/92 0.91 
Control 53 83 67/83 
Symptom scales/items (higher scores represent more severe symptoms) 
Fatigue Intervention 55 22 0/33 
Control 53 11 0/33 0.43 
Nausea and vomiting Intervention 57 0 0/0 
Control 53 0 0/0 0.85 
Pain Intervention 55 0 0/17 
Control 53 0 0/17 0.55 
Dyspnoea Intervention 57 0 0/0 
Control 53 0 0/33 0.2 
Insomnia Intervention 57 0 0/50 
Control 52 33 0/67 0.23 
Appetite loss Intervention 56 0 0/0 
Control 53 0 0/0 0.06 
Constipation Intervention 57 0 0/0 
Control 53 0 0/33 0.02 
Diarrhoea Intervention 55 0 0/0 
Control 53 0 0/33 0.09 
Financial difficulties Intervention 56 0 0/0 
Control 53 0 0/0 0.44 
*IRQ = interquartile range.**P = Mann–Whitney U test.
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Table 4 Data at weeks 3, 6 and 12 for intervention and control groups for symptom assessment scale 
Assessment at week 3 Assessment at week 6 Assessments at week 12 
Symptoms self assessment  Randomisation
Patient Median IQR  25/75 **P Patient Median IQR  25/75 **P Patient Median IQR  25/75 **P visual analogue scale
numbers numbers numbers
Urinary frequency Intervention 54 17.2 2/48 0.69 52 11.7 1/38 0.43 26 2 0/13 0.63 
Control 52 17 1/41 53 7 0/39 30 6 0/31 
Urinary leakage Intervention 48 2 0/12 0.72 50 1 0/10 0.5 26 0 0/3 0.61 
Control 53 3 0/14 52 1 0/17 28 0 0/11 
Nocturia Intervention 54 3 0/39 0.14 53 22 8/47 0.55 26 12 4/34 0.24 
Control 53 16 1/37 52 26.7 9/60 27 22.5 6/45 
Pain with passing urine Intervention 52 6 0/26 0.79 52 4 0/27 0.95 26 0 0/7 0.43 
Control 52 4 0/28 53 3 0/27 28 3 0/11 
Activity and bladder symptoms Intervention 54 14.5 0/39 0.87 54 6 0/32 0.73 27 1 0/19 0.37 
Control 54 13 1/39 53 8 0/32 30 7 0/31 
Diarrhoea Intervention 54 8 0/28 0.76 51 3 0/14 0.37 26 0 0/7 0.23 
Control 54 7 2/24 53 6 0/16 30 3 0/18 
Constipation Intervention 53 1 0/13 0.17 53 2 0/15 0.77 26 0 0/4 0.5 
Control 54 1 0/6 52 1 0/14 30 0 0/4 
Cramp or abdominal pain Intervention 53 0 0/6 0.61 50 1 0/5 0.38 27 0 0/0 0.27 
Control 52 1 0/6 52 0 0/2 29 0 0/3 
Sore anus Intervention 52 8 1/26 0.63 53 10 0/22 0.73 26 0 0/17 0.97 
Control 53 6 0/32 51 7 0/32 27 1 0/13 
Activity and bowel symptoms Intervention 54 7 0/22 0.65 54 1 0/18 0.82 27 0 0/1 0.13 
Control 54 2 0/27 53 1 0/22 30 1 0/12 
Fatigue Intervention 54 14.3 2/44 0.6 51 14.3 0/39 0.64 25 6 0/26 0.38 
Control 51 12 4/24 53 12.7 4/25 30 8 0/38 
Sickness Intervention 52 0 0/2 0.99 51 0 0/3 0.41 26 0 0/0 0.19 
Control 51 0 0/1 53 0 0/1 29 0 0/1 
Feeling Unwell Intervention 54 8 0/28 0.3 54 5 0/24 0.77 27 0 0/13 0.24 
Control 54 2 0/17 53 4 0/15 30 2 0/14 
*IQR = interquartile range.**P = Mann–Whitney U tests.Comparison of symptoms over time 
The time course of symptoms in the treatment group were
compared using univariate and multivariate analysis to take
account of variations in presenting factors. 
The median of the maximum symptom score for each
symptom over the time of radiotherapy treatment was used to
define high and low symptom score groups of men. This created
a dichotomous variable to compare men with high symptom
scores with those with low symptom scores. Logistic regression
was then used to model causative factors for high symptom
scores. 
In the univariate analysis, high symptom scores had no signifi-
cant relationship with the randomised treatment group. In the
multivariate analysis controlling for demographic, disease- and
treatment-related factors there was no significant relationship
between treatment group and symptom scores over the time of
radiotherapy (Table 6). 
Patient satisfaction 
Men were overall very content with their clinical care in both
groups. However, those in the intervention group were significantly
more satisfied (P < 0.002) with their follow-up care than those men
attending the control group (Table 7). The nurse-led clinic was
perceived as providing a greater amount of information: 91% (50)
of the men in the intervention group were positive about this aspect,
compared to 82% (42) in the control group. All patients rated the
experience of radiotherapy treatment very positively, but in the
control group 23% of men commented on the lack of continuity in
follow-up care. Men in the intervention group felt well informed,
felt their concerns were taken seriously, liked the continuity and the
fact that their family was included in the consultations. 
Economic evaluation 
The intervention provided cost benefits (Table 8). Service costs
were significantly higher (P < 0.001) for those in the control group
with a total cost saving of 31% (£10 548) in service costs, 38%
(£344) in microbiology costs and 7% (£50) in the cost of medica-
tion. In total a 31% (£10 942) saving in health care costs were seen
in the intervention group, compared with the control group.
Service costs were lower in the intervention group, partly as the
result of the nurse being cheaper to employ, as well as patients
having less additional services. The cost of the nurse per clinic
visit, was less (£71 for medical appointments compared with £52
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Table 5 Data at weeks 6 and 12 for intervention and control groups for quality of life variables 
Assessment at week 6 Assessment at week 12 
Measurements Randomisation
Patient Median *IQR25/75 **P Patient Median *IQR  25/75 **P
numbers numbers
Functional scales (higher scores represent better functioning) 
Physical functioning Intervention 53 100 80/100 47 100 100/100 
Control 44 100 80/100 0.49 43 100 80/100 0.05 
Role functioning Intervention 53 100 100/100 48 100 100/100 
Control 47 100 100/100 0.38 44 100 100/100 0.68 
Emotional functioning Intervention 54 92 75/100 47 92 75/100 
Control 43 92 67/100 0.45 43 83 67/100 0.24 
Cognitive functioning Intervention 52 100 67/100 48 100 83/100 
Control 44 92 67/100 0.84 41 83 83/100 0.89 
Social functioning Intervention 53 100 67/100 47 100 83/100 
Control 44 83 67/100 0.09 43 100 67/100 0.44 
Global health status/QoL
Global quality of life Intervention 54 75 58/83 48 79 67/83 
Control 44 67 58/83 0.29 43 67 58/83 0.16 
Symptom scales/Items (higher scores represent more symptoms) 
Fatigue Intervention 51 22 0/44 48 22 0/33 
Control 46 33 11/44 0.7 44 22 0/33 0.85 
Nausea and vomiting Intervention 53 0 0/0 46 0 0/0 
Control 47 0 0/0 0.12 43 0 0/0 0.06 
Pain Intervention 50 0 0/16 47 0 0/17 
Control 46 0 0/21 0.45 45 17 0/17 0.36 
Dyspnoea Intervention 54 0 0/33 48 0 0/33 
Control 47 0 0/33 0.42 45 0 0/33 0.73 
Insomnia Intervention 53 33 0/67 48 33 0/33 
Control 47 33 0/67 0.91 45 33 0/33 0.91 
Appetite loss Intervention 54 0 0/0 48 0 0/0 
Control 47 0 0/0 0.38 45 0 0/0 0.71 
Constipation Intervention 53 0 0/33 48 0 0/33 
Control 46 0 0/33 0.06 45 33 0/33 0.01 
Diarrhoea Intervention 54 0 0/33 46 0 0/33 
Control 46 17 0/33 0.51 45 0 0/33 0.58 
Financial difficulties Intervention 54 0 0/0 46 0 0/0 
Control 44 0 0/0 0.02 43 0 0/0 0.68 
*IRQ = interquartile range.** P = Mann–Whitney U tests.1862 S Faithfull et al 
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Table 6 Results of logistic regression analysis of high/low self assessed symptoms scores 
Factor No. high symptom  Univariate analysis   P Multivariate analysis  Pa
score% Odds ratio (OR) 95% CI Odds ratio (OR) 95% CI
Constipation 
Control 26/56 (46.4) 1 1 
Intervention 32/58 (55.2) 1.4 (0.6–2.9) 0.35 2.5 (0.7–8.2) 0.12 
Cramps 
Control 24/55 (43.6) 1 1 
Intervention 26/58 (44.8) 1.0 (4.9–2.2) 0.89 1.9 (0.7–5.3) 0.19 
Sore anus
Control 27/56 (48.2) 1 1 
Intervention 28/55 (50.9) 1.11 (0.52–2.3) 0.77 1.4 (0.59–3.73) 0.4 
Diarrhoea 
Control 28/56 (50) 1
Intervention 29/58 (50) 1 (0.4–2.08) 0.99 0.97 (0.3–2.4) 0.96 
Fatigue 
Control 25/56 (44.6) 1 1 
Intervention 32/58 (55.2) 1.52 (0.72–3.1) 0.26 1.7 (0.7–4.42) 0.21 
Urinary frequency 
Control 27/55 (49.1) 1
Intervention 28/58 (48.3) 0.9 (0.46–2.02) 0.93 1.10 (0.45–2.64) 0.82 
Leakage 
Control 30/56 (53.6) 1 1 
Intervention 26/58 (44.8) 0.7 (0.33–1.47) 0.35 1.0 (0.4–2.44) 0.99 
Nocturia 
Control 29/56 (51.8) 1 
Intervention 28/58 (48.3) 0.8 (0.4–1.81) 0.7 0.9 (0.37–2.15) 0.81 
Pain when passing urine 
Control 30/56 (53.6) 1 
Intervention 26/58 (44.8) 0.7 (0.33–1.47) 0.35 0.88 (0.37–2.05) 0.77 
aMultiple regression controlling for demographic and treatment variables. 
Table 7 Frequency data from survey of satisfaction with care 
Frequency data from survey of satisfaction with care 
Question Number of  Median Interquartile  P* 
patients range
Satisfaction with medical and nursing care
Global score Intervention 55 97.5 82.5/100 < 0.002 
Control 52 85 68.1/96.6 
Question: How did you  Patient  Negative  Percentage Neutral  Percentage Positive  Percentage 
feel about numbers response response response
1. The technical aspects  Intervention 55 0 0% 2 4% 53 96% 
of treatment Control 52 0 0% 3 6% 49 94%
2. The amount of information  Intervention 55 5 9% 0 0% 50 91% 
you were given Control 51 4 8% 5 10% 42 82%
3. Your worries and concerns  Intervention 54 0 0% 3 6% 51 94% 
were taken seriously Control 52 1 2% 8 15% 43 83%
4. That checks were made to  Intervention 55 0 0% 2 4% 53 96% 
see if you were okay Control 52 2 4% 5 10% 45 86% 
5. The way things were  Intervention 55 0 0% 2 4% 53 96% 
explained to you Control 51 1 2% 6 12% 44 86% 
6. That your family  Intervention 55 3 5% 6 11% 46 84% 
were considered Control 50 4 8% 10 20% 36 72% 
7. The amount that was  Intervention 55 0 0% 4 7% 51 93% 
known about your case Control 51 1 2% 9 18% 41 80% 
8. That you knew who  Intervention 55 1 2% 3 5% 51 93% 
was looking after you Control 52 8 15% 10 19% 34 65% 
9. That your symptoms were  Intervention 55 0 0% 2 4% 53 96% 
managed as best they could Control 51 1 2% 3 6% 47 92% 
10. The awareness of  Intervention 55 1 2% 2 4% 52 94% 
your needs Control 51 3 6% 4 8% 44 86%
*Mann–Whitney U test.for the nurse-led follow-up), but also in the intervention there was
reduced outpatient attendance (Table 9). These overall and service
cost savings would only be realised if the nurse-led service was
provided as a component of existing care or by re-allocating
existing health-care resources. 
The median cost of outpatient attendance per patient was £280
in the intervention group, with a range of £288–351, whilst in the
control group the median cost per patient was £426, with a range
of £355–487. The reason for this was the smaller number of clinic
appointments in the intervention group. Overall medication and
investigations such as microbiology accounted for only a small
proportion of the economic costs, and it was the changes to the
way that outpatient care was managed that reduced the health-care
costs overall. Replacing routine outpatient appointments with tele-
phone contact was cheaper. 
DISCUSSION 
This study was designed to evaluate a nurse-led clinic not only in
patient outcomes such as quality of life, toxicity, self-assessed
symptoms but also its effect on service provision. Statistically
significant differences were seen between the two-randomised
groups in symptoms within the first week of radiotherapy treat-
ment. This diminished over the course of radiotherapy and over
time there was little evidence of differences between the 2 groups.
The differences seen in the first week of radiotherapy are unlikely
to be due to bias in patient allocation because of the randomised
nature of the study and similar demographic and treatment char-
acteristics between the 2 groups. We believe that the brief inter-
vention at the start of radiotherapy by the nurse in discussing
symptoms, providing information and practical strategies for
support was helpful and secured these advantages. Further work in
exploring the benefits of this intervention are required. 
The hypothesis of this study was based on the premise that the
intervention would be able to influence urinary symptoms and
quality of life at 6 weeks. At the time of setting up of this study
little was known as to the extent of self-assessed morbidity in men
with prostate cancer. There has been in recent years a growing body
of literature exploring prostate cancer and its effect on men’s quality
of life. These studies have identified that men have high quality of
life and that the conventional global quality-of-life assessments are
insensitive in this patient population (Kemmler et al, 1999).
However, although we were unable to demonstrate a difference in
radiotherapy morbidity the study provides useful data in evalu-
ating such health-care change. Over 50% of the patients in the first
week of radiotherapy had disease-related symptoms, such as
urinary frequency or nocturia, which were felt to impact on daily
activities. Much of the intervention work was in mediating the
effect of these rather than the acute side effects that were initially
the focus of this study. This is important to remember when
considering the benefits of this approach and the training or skills
of the practitioner involved in monitoring patients. Many centres
have developed innovative roles for therapeutic radiographers,
whose skills may be different in relation to that of the nurse in
managing disease-related symptoms. This was demonstrated in
that 50% of the queries from bleep contact were not related to
radiotherapy side effects but more general health-related concerns.
This should be considered when developing innovative roles in
that side effects arise for patients within the context of the wider
cancer experience. Comparison, between the 2 randomised groups,
in the severity of acute side effects showed few differences.
Interventions to alleviate or mediate acute side effects have
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Table 8 Cost savings between randomised groups groups 
Service costs Microbiology Medication Total costs 
Control (n = 57) £33 650 £901 £755 £35 306 
Intervention (n = 58) £23 102 £557 £704 £24 363 
Total £56 751 £1458 £1460 £59 668 
Saving £10 548 £345 £51 £10 943 
Percentage saving 31% 38% 7% 31% 
*P 0 0.01 0.87 0 
*P = Mann–Whitney U test. 
Table 9 Service costs 
Randomised group Median IQR range* Sum cost All P* 
Overnight stays Intervention £0 0–0 £3005 0.31 
(Cost £250.44) Control £0 0–0 £2254 £5259
Day case Intervention £0 0–0 $370 0.30 
(Cost £185) Control £0 0–0 £925 £1295 
Outpatient appointments Intervention £281 £228–351 £16 059 0.001 
(Cost**) Control £426 £355–487 £24 867 £40 926 
Telephone contact Intervention £54 
(Cost for 2 calls £0.93p) Control £0 £54 
Radiotherapy nurse Intervention £52 £0–105 £3614 0.70 
(Cost £52.37p) Control £52 £0–105 £5604 £9217 
Total service costs Intervention £23 102 0.001 
Control £33 650 £56 751 
*Mann–Whitney U test. **Cost for Dr £71.06 and for nurse £52.37. focused on cystitis and diarrhoea. However, in this study, nocturia
and fatigue were 2 of the most troubling symptoms that impacted
on physical functioning. 
The issue of autonomy is often raised as a potential barrier to the
development of nursing roles, but this study was designed and 
co-ordinated in collaboration with medical colleagues. Patients
receiving treatment were discussed and their treatment audited on
a weekly basis by the multidisciplinary team. The consultant there-
fore delegated the day-to-day management of the patients’ care to
the specialist nurse. The model explored within this study was of
‘nurse-led’ care rather than ‘nurse-alone’ care, which is an impor-
tant distinction as the support of the multidisciplinary team is
essential to be able to function in such a role. Patients commented
that one of the benefits of nurse-led care was the continuity of
care. Translating this service into a wider patient population would
increase the caseload of the nurse, however the fundamental
change away from routine appointments and the use of telephone
contact could reduce workload. However, some cancer patient
groups may not be suitable for nurse-led care, for example men
with bladder cancer required more medical services and a wider
extent of medication than men with prostate cancer. Eligibility
criteria would help in determining those most suitable for nurse-
led care. 
The number of statistical tests used when evaluating differences
between groups across the various measures must be considered
and thus ‘borderline’ P values (close to the conventional P = 0.05
level) should be interpreted with caution. The study was not
designed to consider subtle differences and patient numbers would
have to increase substantially in order to detect small differences
with an acceptable level of power. 
The secondary hypothesis was confirmed in that nurse-led care
provided cost savings and patients were more satisfied with health
care. Positive benefits were identified in the evaluation of nurse-
led care. Overall during the course of the study there was an
approximate cost saving of 31%. The introduction of specialist
nursing care in other health-care areas such as paediatrics (Brooten
et al, 1986) or mental illness (Brooker and Buuterworth, 1991) has
previously identified cost savings. Previous studies have identified
that nursing care is cheaper than medical care but they have not
taken this forward into realising the savings by reducing medical
staffing levels and transferring resources to nursing posts. In this
study the cost savings were due in main to changes in the way
services were delivered, reducing both outpatient appointments
and inpatient stays. The nurse-led service was placed as part of
existing outpatient services. 
The ability to generalise these cost savings into wider practice
settings would require not only a shift in how care was organised
but a movement of resources. The methods of working out the
economics of health care are inevitably an oversimplification as the
units of analysis used by health-care services in costing elements of
care are rarely based on true financial cost. However, what this
study offers is a comparison of how a change in radiotherapy
follow-up can be reflected in the utilisation of hospital services.
The existing divisions in radiotherapy care, funding systems and
available management of resources all combine to impede changes
in practice. If funding came as a single element for supportive care
rather than specific posts then care could be organised more effi-
ciently according to the most appropriate person to deliver that
care. This could be a specialist nurse, therapy radiographer or
physician. To realise these economic benefits a movement towards
a more patient-centred system is required. 
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